292 related articles for article (PubMed ID: 27694262)
1. Quality of life at 6 months in the Idiopathic Intracranial Hypertension Treatment Trial.
Bruce BB; Digre KB; McDermott MP; Schron EB; Wall M;
Neurology; 2016 Nov; 87(18):1871-1877. PubMed ID: 27694262
[TBL] [Abstract][Full Text] [Related]
2. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial.
; Wall M; McDermott MP; Kieburtz KD; Corbett JJ; Feldon SE; Friedman DI; Katz DM; Keltner JL; Schron EB; Kupersmith MJ
JAMA; 2014 Apr 23-30; 311(16):1641-51. PubMed ID: 24756514
[TBL] [Abstract][Full Text] [Related]
3. Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT).
Wall M; Johnson CA; Cello KE; Zamba KD; McDermott MP; Keltner JL;
Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):805-12. PubMed ID: 26934136
[TBL] [Abstract][Full Text] [Related]
4. Quality of life in idiopathic intracranial hypertension at diagnosis: IIH Treatment Trial results.
Digre KB; Bruce BB; McDermott MP; Galetta KM; Balcer LJ; Wall M;
Neurology; 2015 Jun; 84(24):2449-56. PubMed ID: 25995055
[TBL] [Abstract][Full Text] [Related]
5. Papilledema Outcomes from the Optical Coherence Tomography Substudy of the Idiopathic Intracranial Hypertension Treatment Trial.
;
Ophthalmology; 2015 Sep; 122(9):1939-45.e2. PubMed ID: 26198807
[TBL] [Abstract][Full Text] [Related]
6. Factors Affecting Visual Field Outcomes in the Idiopathic Intracranial Hypertension Treatment Trial.
Cello KE; Keltner JL; Johnson CA; Wall M;
J Neuroophthalmol; 2016 Mar; 36(1):6-12. PubMed ID: 26618282
[TBL] [Abstract][Full Text] [Related]
7. The Idiopathic Intracranial Hypertension Treatment Trial: A Review of the Outcomes.
Smith SV; Friedman DI
Headache; 2017 Sep; 57(8):1303-1310. PubMed ID: 28758206
[TBL] [Abstract][Full Text] [Related]
8. A randomised controlled trial of treatment for idiopathic intracranial hypertension.
Ball AK; Howman A; Wheatley K; Burdon MA; Matthews T; Jacks AS; Lawden M; Sivaguru A; Furmston A; Howell S; Sharrack B; Davies MB; Sinclair AJ; Clarke CE
J Neurol; 2011 May; 258(5):874-81. PubMed ID: 21161260
[TBL] [Abstract][Full Text] [Related]
9. Safety and Tolerability of Acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial.
ten Hove MW; Friedman DI; Patel AD; Irrcher I; Wall M; McDermott MP;
J Neuroophthalmol; 2016 Mar; 36(1):13-9. PubMed ID: 26587993
[TBL] [Abstract][Full Text] [Related]
10. The Relationship Between Optic Disc Volume, Area, and Frisén Score in Patients With Idiopathic Intracranial Hypertension.
Sheils CR; Fischer WS; Hollar RA; Blanchard LM; Feldon SE;
Am J Ophthalmol; 2018 Nov; 195():101-109. PubMed ID: 30081012
[TBL] [Abstract][Full Text] [Related]
11. Acetazolamide-Induced Nephrolithiasis in Idiopathic Intracranial Hypertension Patients.
Au JN; Waslo CS; McGwin G; Huisingh C; Tanne E
J Neuroophthalmol; 2016 Jun; 36(2):126-30. PubMed ID: 26606175
[TBL] [Abstract][Full Text] [Related]
12. Optic disc haemorrhages at baseline as a risk factor for poor outcome in the Idiopathic Intracranial Hypertension Treatment Trial.
Wall M; Thurtell MJ;
Br J Ophthalmol; 2017 Sep; 101(9):1256-1260. PubMed ID: 28130349
[TBL] [Abstract][Full Text] [Related]
13. The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes From Months 6-12.
Wall M; Kupersmith MJ; Thurtell MJ; Moss HE; Moss EA; Auinger P;
Am J Ophthalmol; 2017 Apr; 176():102-107. PubMed ID: 28104417
[TBL] [Abstract][Full Text] [Related]
14. Retinal vessel diameter changes after 6 months of treatment in the Idiopathic Intracranial Hypertension Treatment Trial.
Moss HE; Hollar RA; Fischer WS; Feldon SE
Br J Ophthalmol; 2020 Oct; 104(10):1430-1434. PubMed ID: 31949093
[TBL] [Abstract][Full Text] [Related]
15. Puberty as a risk factor for less favorable visual outcome in idiopathic intracranial hypertension.
Stiebel-Kalish H; Kalish Y; Lusky M; Gaton DD; Ehrlich R; Shuper A
Am J Ophthalmol; 2006 Aug; 142(2):279-83. PubMed ID: 16876509
[TBL] [Abstract][Full Text] [Related]
16. Management of Peripapillary Choroidal Neovascular Membrane in Patients With Idiopathic Intracranial Hypertension.
Ozgonul C; Moinuddin O; Munie M; Lee MS; Bhatti MT; Landau K; Van Stavern GP; Mackay DD; Lebas M; DeLott LB; Cornblath WT; Besirli CG
J Neuroophthalmol; 2019 Dec; 39(4):451-457. PubMed ID: 30951011
[TBL] [Abstract][Full Text] [Related]
17. The use of acetazolamide in idiopathic intracranial hypertension during pregnancy.
Lee AG; Pless M; Falardeau J; Capozzoli T; Wall M; Kardon RH
Am J Ophthalmol; 2005 May; 139(5):855-9. PubMed ID: 15860291
[TBL] [Abstract][Full Text] [Related]
18. Headache determines quality of life in idiopathic intracranial hypertension.
Mulla Y; Markey KA; Woolley RL; Patel S; Mollan SP; Sinclair AJ
J Headache Pain; 2015; 16():521. PubMed ID: 25982204
[TBL] [Abstract][Full Text] [Related]
19. Acetazolamide for the treatment of idiopathic intracranial hypertension.
Supuran CT
Expert Rev Neurother; 2015; 15(8):851-6. PubMed ID: 26154918
[TBL] [Abstract][Full Text] [Related]
20. Role of vitamin A metabolism in IIH: Results from the idiopathic intracranial hypertension treatment trial.
Libien J; Kupersmith MJ; Blaner W; McDermott MP; Gao S; Liu Y; Corbett J; Wall M;
J Neurol Sci; 2017 Jan; 372():78-84. PubMed ID: 28017254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
